Samples Of Oral Polio Vaccine Found Adulterated: MoS Health

New Delhi :Two samples of a batch of bivalent oral polio vaccine (bOPV) were found to be adulterated and containing type 2 polio virus by the Central Drugs Laboratory (CDL), Minister of State for Health Ashwini Kumar Choubey has told the Rajya Sabha in reply to unstarred Q. No. 108. Some vials of the oral polio vaccines, manufactured by a Ghaziabad-based pharmaceuticals company, contaminated with the type-2 polio virus were administered to children in Maharashtra, Telengana, and Uttar Pradesh, the ministry officials had confirmed.

Several samples of the vaccine manufactured by M/s BioMed Pvt Ltd were drawn by drugs inspectors of CDSCO and sent for test at Central Drugs Laboratory (CDL) Kasauli.

“Two samples of a batch of Poliomyelitis Vaccine, Live, Oral Indian Pharmacopoeia Bivalent were declared as not of standard quality and deemed to be adulterated by the government analyst, CDL, as per the provisions of the Drugs and Cosmetics Act, 1940 as the samples were found to contain Polio Virus Type 2,” Choubey said Tuesday in a reply to the Parliament.

The Central Drugs Standard Control Organisation (CDSCO) then had issued a show-cause notice to the firm and ordered it to stop production of all human vaccines manufactured at the said facility.

Simultaneously, the drugs inspector of CDSCO had filed a police complaint.

In addition, the Ministry of Health has issued instructions to all states/UTs to stop use of bOPV supplied by M/s BioMed Pvt Ltd.

“Further, in the identified districts of Telangana and Uttar Pradesh, where the suspected batch of OPV that was not of standard quality was used, special vaccination campaigns with inactivated polio vaccine (IPV) have been carried out to boost immunity against type 2 polio virus,” he said.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’